Literature DB >> 9716159

Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo.

P G Lerch1, M O Spycher, J E Doran.   

Abstract

A reconstituted high density lipoprotein (rHDL) prepared for clinical use was tested for its influence on platelet activity modulated by various stimuli. In a first series of in vitro experiments, rHDL was added to blood in a concentration series, and platelet rich plasma (PRP) was isolated. Platelets were stimulated with arachidonic acid, collagen, epinephrine or ADP, and platelet aggregation was assessed. rHDL mediated a dose dependent inhibition of the platelet activity. With purified platelets rHDL inhibited the release reaction induced by collagen, but not by thrombin, as measured by CD62P (P-Selectin) expression on the plasma membrane. Ex vivo experiments were performed with PRP from volunteers, previously infused with 25 mg rHDL/kg body weight and 40 mg rHDL/kg body weight, respectively. Platelet activity in PRP was assessed before, and up to 30 h after the end of the rHDL infusion. A transient inhibition of the platelet aggregation induced by arachidonic acid and collagen was observed which was more pronounced in the group receiving 40 mg rHDL/kg body weight. In both groups of experiments, in vitro and ex vivo, the inhibition of the platelet activity was also dependent on the stimulus used.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716159

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  23 in total

1.  Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.

Authors:  David O Osei-Hwedieh; Marcelo Amar; Dmitri Sviridov; Alan T Remaley
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 2.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 3.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 4.  Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis.

Authors:  John A Farmer; Joshua Liao
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

5.  Old HDL learns a new (anti-inflammatory) trick.

Authors:  Justin I Odegaard; Ajay Chawla
Journal:  Nat Immunol       Date:  2014-02       Impact factor: 25.606

Review 6.  Novel biological functions of high-density lipoprotein cholesterol.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  Circ Res       Date:  2012-09-28       Impact factor: 17.367

Review 7.  Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis.

Authors:  Jonathan D Smith
Journal:  Curr Opin Investig Drugs       Date:  2010-09

8.  Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation.

Authors:  Stefan Barlage; Carsten Gnewuch; Gerhard Liebisch; Zsuzsanna Wolf; Franz-Xaver Audebert; Thomas Glück; Dieter Fröhlich; Bernhard K Krämer; Gregor Rothe; Gerd Schmitz
Journal:  Intensive Care Med       Date:  2009-08-08       Impact factor: 17.440

Review 9.  HDL therapy today: from atherosclerosis, to stent compatibility to heart failure.

Authors:  C R Sirtori; M Ruscica; L Calabresi; G Chiesa; R Giovannoni; J J Badimon
Journal:  Ann Med       Date:  2019 Nov - Dec       Impact factor: 4.709

Review 10.  Regulation of signal transduction by HDL.

Authors:  Chieko Mineo; Philip W Shaul
Journal:  J Lipid Res       Date:  2013-05-18       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.